ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

8.980 +0.190 (+2.16%)

Streaming Delayed Price Updated: 3:46 PM EDT, Apr 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	2,283,249
Open	8.730
Bid (Size)	8.980 (800)
Ask (Size)	8.990 (1,800)
Prev. Close	8.790
Today's Range	8.695 - 9.070
52wk Range	6.230 - 16.44
Shares Outstanding	157,749,490
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have ou...

Via StockStory

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

Performance

YTD	-24.0%	-24.0%
1 Month	+2.5%	+2.5%
3 Month	-16.0%	-16.0%
6 Month	-24.2%	-24.2%
1 Year	+18.6%	+18.6%

More News

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

March 18, 2026

Via StockStory

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

March 17, 2026

Via StockStory

3 Stocks Under $10 We Think Twice About

March 16, 2026

Via StockStory

Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

March 11, 2026

Via StockStory

3 Small-Cap Stocks We’re Skeptical Of

March 05, 2026

Via StockStory

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

March 04, 2026

Via StockStory

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

February 27, 2026

Via StockStory

1 Russell 2000 Stock Worth Investigating and 2 We Avoid

February 26, 2026

Via StockStory

1 Volatile Stock for Long-Term Investors and 2 Facing Challenges

February 18, 2026

Via StockStory

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

February 17, 2026

Via Chartmill

Tuesday's pre-market session: top gainers and losers ↗

February 17, 2026

Via Chartmill

Nasdaq, S&P 500 Futures Lower As AI Disruption Fears Linger: Why AAPL, ZIM, OCUL, NCLH Are On Traders' Radar Today ↗

February 17, 2026

Via Stocktwits

OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds ↗

February 16, 2026

Via Stocktwits

Wondering what's happening in today's after-hours session? ↗

February 16, 2026

Via Chartmill

Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom

February 16, 2026

Via MarketMinute

Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data

February 16, 2026

Via MarketMinute

Ocular Therapeutix (NASDAQ:OCUL) Misses Q4 CY2025 Revenue Estimates

February 05, 2026

Via StockStory

A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack

January 26, 2026

Via StockStory

3 Cash-Burning Stocks We’re Skeptical Of

January 19, 2026

Via StockStory

1 Healthcare Stock to Consider Right Now and 2 We Find Risky

January 15, 2026

Via StockStory

What's going on in today's pre-market session ↗

January 15, 2026

Via Chartmill

Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗

January 15, 2026

Via Stocktwits

Frequently Asked Questions

Is Ocular Therapeutix, Inc. - Common Stock publicly traded?

Yes, Ocular Therapeutix, Inc. - Common Stock is publicly traded.

What exchange does Ocular Therapeutix, Inc. - Common Stock trade on?

Ocular Therapeutix, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ocular Therapeutix, Inc. - Common Stock?

The ticker symbol for Ocular Therapeutix, Inc. - Common Stock is OCUL on the Nasdaq Stock Market

What is the current price of Ocular Therapeutix, Inc. - Common Stock?

The current price of Ocular Therapeutix, Inc. - Common Stock is 8.980

When was Ocular Therapeutix, Inc. - Common Stock last traded?

The last trade of Ocular Therapeutix, Inc. - Common Stock was at 04/13/26 03:46 PM ET

What is the market capitalization of Ocular Therapeutix, Inc. - Common Stock?

The market capitalization of Ocular Therapeutix, Inc. - Common Stock is 1.42B

How many shares of Ocular Therapeutix, Inc. - Common Stock are outstanding?

Ocular Therapeutix, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.